Table 1.
Baseline characteristics of the study patients
| HDI (2010) classification | ||||
|---|---|---|---|---|
| Characteristic | Very high (N=3659) | High (N=3744) | Medium (N=1898) | p Value |
| Demographics | ||||
| Age (years) | 68.0 (60.0, 76.0) | 65.0 (59.0, 73.0) | 63.0 (56.0, 70.0) | <0.001 |
| Age ≥75 (%) | 1078/3659 (29.5%) | 712/3744 (19.0%) | 278/1898 (14.6%) | <0.001 |
| Female sex (%) | 1405/3659 (38.4%) | 1552/3744 (41.5%) | 684/1898 (36.0%) | <0.001 |
| Weight (kg) | 80.0 (69.0,92.0) | 77.0 (68.0,86.5) | 64.0 (56.0,73.0) | <0.001 |
| Weight <60 kg (%) | 339/3654 (9.3%) | 388/3742 (10.4%) | 660/1898 (34.8%) | <0.001 |
| Presentation characteristics | ||||
| Disease classification (%) | <0.001 | |||
| Unstable angina | 588/3659 (16.1%) | 1417/3744 (37.8%) | 797/1898 (42.0%) | |
| NSTEMI | 3071/3659 (83.9%) | 2327/3744 (62.2%) | 1101/1898 (58.0%) | |
| Killip class II–IV on presentation (%) | 448/3659 (12.2%) | 461/3744 (12.3%) | 218/1898 (11.5%) | 0.638 |
| Cardiovascular risk factors | ||||
| Family history of CAD (%) | 1437/3139 (45.8%) | 841/3305 (25.4%) | 232/1817 (12.8%) | <0.001 |
| Hypertension (%) | 3070/3648 (84.2%) | 3301/3733 (88.4%) | 1231/1897 (64.9%) | <0.001 |
| Hyperlipidaemia (%) | 2700/3573 (75.6%) | 2076/3466 (59.9%) | 456/1807 (25.2%) | <0.001 |
| Diabetes mellitus (%) | 1426/3649 (39.1%) | 1292/3736 (34.6%) | 810/1896 (42.7%) | <0.001 |
| Current/recent smoking* (%) | 857/3595 (23.8%) | 596/3724 (16.0%) | 383/1884 (20.3%) | <0.001 |
| Baseline risk assessment | ||||
| GRACE risk score | 123.0 (106.0,143.0) | 123.0 (106.0,140.0) | 113.0 (99.0,128.0) | <0.001 |
| Prerandomisation treatments | ||||
| Angiography performed (%) | 2448/3658 (66.9%) | 966/3744 (25.8%) | 433/1898 (22.8%) | <0.001 |
| Concomitant medications at randomisation | ||||
| Aspirin (%) | ||||
| Daily dose <100 mg | 1438/3659 (39.3%) | 877/3744 (23.4%) | 793/1898 (41.8%) | <0.001 |
| Daily dose 100–250 mg | 1495/3659 (40.9%) | 2524/3744 (67.4%) | 916/1898 (48.3%) | <0.001 |
| Daily dose >250 mg | 467/3659 (12.8%) | 134/3744 (3.6%) | 71/1898 (3.7%) | <0.001 |
| β-blocker (%) | 3056/3659 (83.5%) | 2966/3744 (79.2%) | 1211/1898 (63.8%) | <0.001 |
| ACE-I/ARB (%) | 2857/3659 (78.1%) | 3023/3744 (80.7%) | 1132/1898 (59.6%) | <0.001 |
| Statin (%) | 3161/3659 (86.4%) | 3078/3744 (82.2%) | 1520/1898 (80.1%) | <0.001 |
Data presented as n/N (%) or as median (25th, 75th centiles).
*Smoking within 30 days of randomisation.
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; CAD, coronary artery disease; GRACE, Global Registry of Acute Coronary Events; NSTEMI, non-ST-segment elevation myocardial infarction.